Seattle Genetics, Inc. and Astellas Pharma Inc. have been granted the FDA Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI). Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to…